CA-SYSDIG
Sysdig, the leader in cloud security powered by runtime insights, today announced that the company was named a Strong Performer — one of only two vendors to receive the recognition — in Gartner Peer Insights “Voice of the Customer” for Cloud Security Posture Management (CSPM) Tools. Sysdig is the only cloud security platform to receive the maximum of five stars in the report, which was derived directly from verified customer feedback, and synthesizes reviews and ratings received as of November 30, 2023.
In addition to receiving the highest overall rating, Sysdig received top marks in each category:
- Product Capabilities: 4.9/5
- Sales Experience: 4.9/5
- Deployment Experience: 4.9/5
- Support Experience: 5/5
As the cloud landscape continues to evolve, Sysdig is at the forefront of cloud security innovation, offering active cloud risk prioritization, vulnerability management, and compliance solutions that go beyond traditional static checks. The company's dedication to providing comprehensive visibility and robust security measures has garnered widespread acclaim from its user base, as it believes is evidenced by its exceptional ratings in the Gartner “Voice of the Customer” report.
"Customers demand and deserve excellence, and we are thrilled to receive such high praise in the Gartner Voice of the Customer report. We believe a 5 out of 5 rating underscores our commitment to CISOs and boards to keep their cloud environment safe," said Knox Anderson, SVP of Product Management at Sysdig. "The industry knows Sysdig as the leader in CNAPP, and now they can feel confident knowing how much our customers love our CSPM solution."
Read the full “Voice of the Customer” report for Cloud Security Posture Management Tools.
Sysdig Customers Praise Productivity Driven by Runtime Insights
The cloud is a dynamic environment where new risks and threats can appear at any time. Most CSPM solutions perform periodic scanning, which only shows static risk and leaves visibility gaps for attackers to exploit. Sysdig empowers organizations to strengthen their cloud security posture through unified findings with active risk prioritization, agentless scanning, attack path analysis, inventory, and real-time security posture checks. Using runtime insights, Sysdig offers unparalleled visibility into active cloud risk, such as real-time configuration changes, suspicious user activity, in-use permission and packages, and workload threats.
By prioritizing active cloud risk, security teams can work more productively by reducing alert fatigue and focusing on addressing the most imminent active threats in their cloud environment. In essence, Sysdig strengthens organizations’ approaches to cloud security posture management, from risk prioritization and vulnerability management to proactive threat detection and compliance, giving them peace of mind that their assets are protected when cloud attacks can happen in a matter of minutes.
Customer feedback highlighted Sysdig's unique approach to CSPM, with users praising the platform for its comprehensive cloud-native security features and ability to improve incident response times. But CSPM is only one part of the Sysdig cloud-native application protection platform (CNAPP), which combines CSPM with cloud workload protection, cloud infrastructure entitlement management, and detection and response in a single security platform to provide customers with end-to-end coverage, from prevention to defense. With Sysdig, organizations can mitigate security issues fast, bolster operational efficiency across multi-cloud environments, and protect the entire software development life cycle.
What our Customers are Saying in Gartner Peer Insights
“I’m genuinely impressed with the level of real-time security posture checks [Sysdig] brings to our cloud infrastructure. The solution has proven to be an invaluable asset in ensuring the safety of our cloud-native application and data.” [Read the full review here]
- Director of Strategic Initiatives; Software Company
“Sysdig CSPM provides unmatched insight and fortified security for cloud-native infrastructure with state-of-art technology. Powered by Falco, it offers comprehensive visibility, empowering businesses to monitor and safeguard cloud assets efficiently…” [Read the full review here]
- VP, IT Security and Risk Management; Financial Company
“Our adoption of Sysdig CSPM was fueled by the growing complexity of our cloud environment. As our presence expanded rapidly, robust security and compliance became imperative. We required a unified solution that could monitor, detect, and manage risk across both AWS and GCP.” [Read the full review here]
- Director of Strategic Initiatives; Software Company
“Since implementing Sysdig CSPM, our incident response time has drastically improved, allowing us to mitigate security issues promptly.” [Read the full review here]
- Information Security Officer; IT Services Company
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product, or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and both are used herein with permission. All rights reserved.
This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available here.
Resources
- Visit Sysdig’s page on Gartner Peer Insights.
- Read Sysdig's blog, “Customers Rate Sysdig 5 Out of 5 in Gartner ‘Voice of the Customer’ for Cloud Security Posture Management Tools” to learn more about the announcement.
- Watch “Sysdig. Secure Every Second.” to learn more about the company.
About Sysdig
In the cloud, every second counts. Attacks move at warp speed, and security teams must protect the business without slowing it down. Sysdig stops cloud attacks in real time, instantly detecting changes in risk with runtime insights and open source Falco. Sysdig correlates signals across cloud workloads, identities, and services to uncover hidden attack paths and prioritize real risk. From prevention to defense, Sysdig helps enterprises focus on what matters: innovation. Sysdig. Secure Every Second.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307640009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
